Gilead Sciences (NASDAQ:GILD)

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

Short Sellers Make a Move on Big Biotechs

The short interest data are out for the most recent settlement date, July 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AMD, Altria, Apple, BP, EA, Enphase, FireEye, Gilead, Mastercard, P&G, 2U and More

Stocks saw profit-taking on Tuesday, but the major indexes were up on Wednesday ahead of the Federal Reserve's expected interest rate cut in the afternoon. Earnings season is proving to ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Aflac, Apple, Chipotle, Coca-Cola, Dell, Dish, Gilead, McDonald’s, Starbucks and More

Stocks were indicated to have a slightly positive open on Monday, but the gains were so small that the outcome of the day seemed far from certain. A mixed earnings ...
Read Full Story »

Major Biotechs See Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, July 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Meet Gilead’s Newest Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) each saw its shares shoot up on Monday after the companies announced a new collaboration. Under the terms of the ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Agilent, Amazon, American Water Works, Crocs, Deere, GE, Gilead, Slack, Teva and More

Stocks were indicated to open marginally higher on Monday, with the indexes effectively at all-time highs based on communication from Federal Reserve Chair Jerome Powell that the agency is expected ...
Read Full Story »

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the most recent settlement date, June 28. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more ...
Read Full Story »

Big Biotechs Scare Off Short Sellers

The short interest data are out for the most recent settlement date, June 14. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Big Biotechs Have Short Sellers on the Run

The short interest data are out for the most recent settlement date, May 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Goldman Sachs Crushes Value and Turnaround Hopes of Gilead Sciences

Gilead Sciences Inc. (NASDAQ: GILD) quite recently has been considered as both a value stock and as a turnaround candidate for long-term views. Goldman Sachs has muted that upside view ...
Read Full Story »

Major Biotechs See a Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, May 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Citigroup Sees Big Upside for 2 of the Largest Biotechs

After quite some time of muted or negative performance, big biotech may be worth a look again. Citigroup analyst Mohit Bansal assumed coverage of the large-cap biotech space and sees ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

Stocks were indicated to open lower by about 1%, with the excuse being the same concerns about a trade war with China. Many investors have to be considering if "sell ...
Read Full Story »